메뉴 건너뛰기




Volumn 56, Issue 5, 2012, Pages 2691-2695

Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTRIAXONE;

EID: 84860204973     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06185-11     Document Type: Article
Times cited : (13)

References (26)
  • 1
    • 84860209263 scopus 로고    scopus 로고
    • Anonymous Genentech, South San Francisco, CA
    • Anonymous. 2010. Rocephin package insert. Genentech, South San Francisco, CA.
    • (2010) Rocephin Package Insert
  • 2
    • 33645766499 scopus 로고    scopus 로고
    • Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: Identification of an in vivo pharmacokinetic-pharmacodynamic target
    • Andes D, Craig WA. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383.
    • (2006) Antimicrob. Agents Chemother. , vol.50 , pp. 1376-1383
    • Andes, D.1    Craig, W.A.2
  • 3
    • 0021832112 scopus 로고
    • In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives
    • Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl A):125-130. (Pubitemid 15079556)
    • (1985) Journal of Antimicrobial Chemotherapy , vol.15 , Issue.SUPPL. A , pp. 125-130
    • Blaser, J.1
  • 4
    • 0344874267 scopus 로고    scopus 로고
    • Linezolid, Levofloxacin, and Vancomycin Against Vancomycin-Tolerant and Fluoroquinolone-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model
    • DOI 10.1592/phco.23.15.1531.31964
    • Cha R, Akins RL, Rybak MJ. 2003. Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Pharmacotherapy 23:1531-1537. (Pubitemid 37485304)
    • (2003) Pharmacotherapy , vol.23 , Issue.12 I , pp. 1531-1537
    • Cha, R.1    Akins, R.L.2    Rybak, M.J.3
  • 5
    • 79954622204 scopus 로고    scopus 로고
    • Review of ceftaroline fosamil microbiology: Integrated FOCUS studies
    • Critchley IA, et al. 2011. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J. Antimicrob. Chemother. 66(Suppl 3): iii45-51.
    • (2011) J. Antimicrob. Chemother. , vol.66 , Issue.SUPPL. 3
    • Critchley, I.A.1
  • 6
    • 79959236262 scopus 로고    scopus 로고
    • Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing
    • Croisier-Bertin D, et al. 2011. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob. Agents Chemother. 55:3557-3563.
    • (2011) Antimicrob. Agents Chemother. , vol.55 , pp. 3557-3563
    • Croisier-Bertin, D.1
  • 7
    • 68349086854 scopus 로고    scopus 로고
    • Emergence of Streptococcus pneumoniae of serotype 19A in France: Molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology
    • Dortet L, Ploy MC, Poyart C, Raymond J. 2009. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn. Microbiol. Infect. Dis. 65:49-57.
    • (2009) Diagn. Microbiol. Infect. Dis. , vol.65 , pp. 49-57
    • Dortet, L.1    Ploy, M.C.2    Poyart, C.3    Raymond, J.4
  • 8
    • 55849104841 scopus 로고    scopus 로고
    • In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime
    • Fenoll A, et al. 2008. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob. Agents Chemother. 52:4209-4210.
    • (2008) Antimicrob. Agents Chemother. , vol.52 , pp. 4209-4210
    • Fenoll, A.1
  • 9
    • 78649873377 scopus 로고    scopus 로고
    • Integrated analysis of FOCUS 1 and FOCUS 2: Randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia
    • File TM, Jr, et al. 2010. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin. Infect. Dis. 51:1395-1405.
    • (2010) Clin. Infect. Dis. , vol.51 , pp. 1395-1405
    • File Jr., T.M.1
  • 10
    • 79954622500 scopus 로고    scopus 로고
    • FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
    • File TM, Jr, et al. 2011. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):iii19-32.
    • (2011) J. Antimicrob. Chemother. , vol.66 , Issue.SUPPL. 3
    • File Jr., T.M.1
  • 12
    • 50949105050 scopus 로고    scopus 로고
    • In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States
    • Ge Y, Biek D, Talbot GH, Sahm DF. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
    • (2008) Antimicrob. Agents Chemother. , vol.52 , pp. 3398-3407
    • Ge, Y.1    Biek, D.2    Talbot, G.H.3    Sahm, D.F.4
  • 13
    • 55849108870 scopus 로고    scopus 로고
    • Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine
    • Jacobs MR, Good CE, Bajaksouzian S, Windau AR. 2008. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin. Infect. Dis. 47:1388-1395.
    • (2008) Clin. Infect. Dis. , vol.47 , pp. 1388-1395
    • Jacobs, M.R.1    Good, C.E.2    Bajaksouzian, S.3    Windau, A.R.4
  • 14
    • 40749096040 scopus 로고    scopus 로고
    • Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: A quarter century of experience
    • DOI 10.1128/JCM.02321-07
    • Jacobs MR, et al. 2008. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol. 46:982-990. (Pubitemid 351379990)
    • (2008) Journal of Clinical Microbiology , vol.46 , Issue.3 , pp. 982-990
    • Jacobs, M.R.1    Good, C.E.2    Beall, B.3    Bajaksouzian, S.4    Windau, A.R.5    Whitney, C.G.6
  • 15
    • 73649093453 scopus 로고    scopus 로고
    • Etiology of community-acquired pneumonia: Increased microbiological yield with new diagnostic methods
    • Johansson, N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. 2010. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin. Infect. Dis. 50:202-209.
    • (2010) Clin. Infect. Dis. , vol.50 , pp. 202-209
    • Johansson, N.1    Kalin, M.2    Tiveljung-Lindell, A.3    Giske, C.G.4    Hedlund, J.5
  • 16
    • 77957892620 scopus 로고    scopus 로고
    • Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: Report from the SENTRY Antimicrobial Surveillance Program (1998-2009)
    • Jones RN, Sader HS, Moet GJ, Farrell DJ. 2010. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn. Microbiol. Infect. Dis. 68:334-346.
    • (2010) Diagn. Microbiol. Infect. Dis. , vol.68 , pp. 334-346
    • Jones, R.N.1    Sader, H.S.2    Moet, G.J.3    Farrell, D.J.4
  • 17
    • 79954622500 scopus 로고    scopus 로고
    • FOCUS 2: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
    • Low DE, et al. 2011. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):iii33-44.
    • (2011) J. Antimicrob. Chemother. , vol.66 , Issue.SUPPL. 3
    • Low, D.E.1
  • 18
    • 59749096800 scopus 로고    scopus 로고
    • In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae
    • McGee L, et al. 2009. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 53:552-556.
    • (2009) Antimicrob. Agents Chemother. , vol.53 , pp. 552-556
    • McGee, L.1
  • 19
    • 77952578858 scopus 로고    scopus 로고
    • Binding of ceftaroline in penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae
    • Moisan H, Pruneau M, Malouin F. 2010. Binding of ceftaroline in penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:713-716.
    • (2010) J. Antimicrob. Chemother. , vol.65 , pp. 713-716
    • Moisan, H.1    Pruneau, M.2    Malouin, F.3
  • 20
    • 64549135399 scopus 로고    scopus 로고
    • Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia
    • Morrissey I, Ge Y, Janes R. 2009. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int. J. Antimicrob. Agents 33:515-519.
    • (2009) Int. J. Antimicrob. Agents , vol.33 , pp. 515-519
    • Morrissey, I.1    Ge, Y.2    Janes, R.3
  • 21
    • 63849299150 scopus 로고    scopus 로고
    • Making sense of scoring systems in community acquired pneumonia
    • Niederman MS. 2009. Making sense of scoring systems in community acquired pneumonia. Respirology 14:327-335.
    • (2009) Respirology , vol.14 , pp. 327-335
    • Niederman, M.S.1
  • 25
    • 77950274114 scopus 로고    scopus 로고
    • Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas
    • Techasaensiri C, Jr, et al. 2010. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas. Pediatr. Infect. Dis. J. 29:294-300.
    • (2010) Pediatr. Infect. Dis. J. , vol.29 , pp. 294-300
    • Techasaensiri Jr., C.1
  • 26
    • 70350498834 scopus 로고    scopus 로고
    • Pathogenesis, treatment, and prevention of pneumococcal pneumonia
    • van der Poll T, Opal SM. 2009. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374:1543-1556.
    • (2009) Lancet , vol.374 , pp. 1543-1556
    • Van Der Poll, T.1    Opal, S.M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.